IPSEF News and Press, Ipsen Sa Ord From 04/22/24

Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise...

2024-04-05 18:31:56 ET Summary Ipsen S.A. is a pharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of commercial drug products. The company generated $3.4bn in revenues in 2023, with a core consolidated net profit of $830m. Ipsen typica...

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development STRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) target STRO-003 has shown robust...

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde ® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and progression-free survival versus nab-paclitaxel and gemcitabine 1 NAPOLI ...

2024-02-13 13:35:30 ET More on Merrimack Financial information for Merrimack Pharmaceuticals Read the full article on Seeking Alpha For further details see: Merrimack spikes as Ipsen wins FDA label expansion for cancer therapy

2024-02-08 01:14:21 ET More on Ipsen: FDA grants priority review of Genfit-Ipsen liver disease drug Genfit stock rallies 20% after hours on data for liver disease drug Historical earnings data for Ipsen S.A. Dividend scorecard for Ipsen S.A. Financial...

Total-sales growth in FY 2023 of 6.7% at CER 1 (3.4% as reported) included strong sales from the growth platforms 2 and good contributions from the new medicines. A core operating margin of 32.0% (IFRS operating margin of 26.1%), based on further enrichment of the pipeline and accelerated...

2023-12-19 09:10:24 ET Summary Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negati...

2023-12-12 10:33:17 ET More on AbbVie, Evolus, etc. AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth AbbVie upgraded at Goldman ...

PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today...